Graham Fletcher, Ph.D.
Chief Operating Officer, Disease Modeling Division
Dr. Fletcher joined the team in 2024. As Chief Operating Officer of the Disease Modeling Division of GD3, he provides leadership, oversight, and coordination for developing and managing operational components, including IACUC and GLP compliance activities and internal study scheduling. He works closely with clients and the Business Development team to understand their needs, design projects, and oversee their studies.
Dr. Fletcher is an accomplished preclinical and clinical drug development scientist and pharmacologist who has held senior roles in small molecule and therapeutic antibody programs. He brought to the team over 20 years of experience covering the drug development process from target discovery and validation through Phase I/II clinical trials with particular therapeutic expertise in Oncology and Immuno-oncology (IO). Dr. Fletcher has extensive experience in team and project management, leading multidisciplinary teams to take three oncology drugs from candidate selection through IND development into nine clinical trials. He deeply understands the drug development process and oncology and IO, encompassing biological, translational, and clinical science. He previously held positions with EntreMed Inc. as a Research Scientist III, Campbell Family Institute, within the University Health Network, Toronto and Treadwell Therapeutics as Head of Preclinical Development, and Medicenna Therapeutics as Director of Clinical Science.
Dr. Fletcher received a BSc in Molecular Biology at Edinburgh University in Edinburgh, Scotland. He earned a Ph.D. in Cell Biology from the University of Cambridge in Cambridge, United Kingdom. Dr. Fletcher is an author of over 20 publications and patents.
Dr. Fletcher joined the team in 2024. As Chief Operating Officer of the Disease Modeling Division of GD3, he provides leadership, oversight, and coordination for developing and managing operational components, including IACUC and GLP compliance activities and internal study scheduling. He works closely with clients and the Business Development team to understand their needs, design projects, and oversee their studies.
Dr. Fletcher is an accomplished preclinical and clinical drug development scientist and pharmacologist who has held senior roles in small molecule and therapeutic antibody programs. He brought to the team over 20 years of experience covering the drug development process from target discovery and validation through Phase I/II clinical trials with particular therapeutic expertise in Oncology and Immuno-oncology (IO). Dr. Fletcher has extensive experience in team and project management, leading multidisciplinary teams to take three oncology drugs from candidate selection through IND development into nine clinical trials. He deeply understands the drug development process and oncology and IO, encompassing biological, translational, and clinical science. He previously held positions with EntreMed Inc. as a Research Scientist III, Campbell Family Institute, within the University Health Network, Toronto and Treadwell Therapeutics as Head of Preclinical Development, and Medicenna Therapeutics as Director of Clinical Science.
Dr. Fletcher received a BSc in Molecular Biology at Edinburgh University in Edinburgh, Scotland. He earned a Ph.D. in Cell Biology from the University of Cambridge in Cambridge, United Kingdom. Dr. Fletcher is an author of over 20 publications and patents.
